Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Hormone Receptor Positive (HR+) Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT02692755
What this trial is testing

Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer

Who this might be right for
Hormone Receptor Positive HER-2 Negative Breast Cancer
Georgetown University 35
Testing effectiveness (Phase 2)Looking for participantsNCT04965766
What this trial is testing

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerAdvanced Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris 139
Post-approval studies (Phase 4)Study completedNCT02679755
What this trial is testing

Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 252
Large-scale testing (Phase 3)Active Not RecruitingNCT04862663
What this trial is testing

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 893
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07716046
What this trial is testing

Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast CancerHormone Receptor-positive Breast Cancer+1 more
Fudan University 240
Early research (Phase 1)Study completedNCT06253195
What this trial is testing

BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorHormone-receptor-positive Breast Cancer+4 more
BeOne Medicines 33
Not applicableNot Yet RecruitingNCT07701070
What this trial is testing

SHIELD: Surveillance of HR+/HER2- : Implementing ESR1m Long-term Monitoring and Detection in 1L aBC

Who this might be right for
Advanced Breast Cancer
AstraZeneca 3,000
Testing effectiveness (Phase 2)Study completedNCT04596150
What this trial is testing

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Who this might be right for
NeoplasmsBreast NeoplasmsBreast Neoplasms, Triple-Negative+2 more
CytomX Therapeutics 125
Large-scale testing (Phase 3)Looking for participantsNCT06982521
What this trial is testing

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Who this might be right for
PIK3CA MutationHER2- Negative Breast CancerHormone Receptor Positive Tumor+3 more
Relay Therapeutics, Inc. 540
Testing effectiveness (Phase 2)Looking for participantsNCT07227233
What this trial is testing

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

Who this might be right for
Breast Cancer
University of California, San Diego 105
Early research (Phase 1)Active Not RecruitingNCT06299124
What this trial is testing

A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors

Who this might be right for
Breast CancerAdvanced Solid Tumor
Regor Pharmaceuticals Inc. 40
Testing effectiveness (Phase 2)Study completedNCT03839823
What this trial is testing

Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 222
Large-scale testing (Phase 3)Study completedNCT03096847
What this trial is testing

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced Metastatic Breast Cancer
Novartis Pharmaceuticals 502
Testing effectiveness (Phase 2)Looking for participantsNCT07612891
What this trial is testing

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor

Who this might be right for
Breast Cancer (Locally Advanced or Metastatic)Advanced Solid CancersMetastatic (Stage IV) Breast Cancer+2 more
Shenzhen Ionova Life Sciences Co., Ltd.
Testing effectiveness (Phase 2)UnknownNCT05806047
What this trial is testing

Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvant Therapy

Who this might be right for
Hormone Receptor-positive Advanced Breast Cancer
Fudan University 23
Early research (Phase 1)Looking for participantsNCT07310420
What this trial is testing

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

Who this might be right for
Advanced Breast CancerEarly Breast Cancer
TerSera Therapeutics LLC 176
Testing effectiveness (Phase 2)Study completedNCT03822468
What this trial is testing

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 376
Testing effectiveness (Phase 2)Looking for participantsNCT07180160
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Wenjin Yin 123
Testing effectiveness (Phase 2)UnknownNCT05808582
What this trial is testing

Chidamide Combined With Fulvestrant for HR+/HER2-advanced Breast Cancer

Who this might be right for
Hormone Receptor-positive Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 60
Large-scale testing (Phase 3)Ended earlyNCT01633060
What this trial is testing

A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 432
Next Page
201